         Taxiarchis V. Kourelis 1 , Samih H. Nasr 2 , Angela Dispenzieri 1 , Shaji K. Kumar 1 , Morie A. Gertz 1 , Fernando C. Fervenza 3 , Francis K. Buadi 1 , Martha Q. Lacy 1 , Stephen B. Erickson 3 , Fernando G. Cosio 3 , Prashant Kapoor 1 , John A. Lust 1 , Suzanne R. Hayman 1 , Vincent Rajkumar 1 , Steven R. Zeldenrust 1 , Stephen J. Russell 1 , David Dingli 1 , Yi Lin 1 , Wilson Gonsalves 1 , Elizabeth C.Lorenz 3 , Ladan Zand 3 , Robert A. Kyle 1 and Nelson Leung 1 1 Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN. 2 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN. 3 Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.  : Nelson Leung, MD Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA Phone: 507;284;8712 Fax: 507;266;7891, E;mail: leung.nelson@mayo.edu  : MIDD renal outcomes : monoclonal, immunoglobulin, deposition, renal, significance, proteasome inhibitor.   : 243   : 4153  : 26 : 2, : 2 This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an ‘Accepted Article’, doi: 10.1002/ajh.24528 This article is protected by copyright. All rights reserved.